Objective: Although insulin analogs have dramatically changed diabetes treatment, scarce evidence is available on those effects. We aimed to explore whether glycemic control had improved, the use of insulin analogs had been increased, and hypoglycemic events had decreased over time in Japanese pediatric patients with type 1 diabetes (T1D). Conclusions: Glycemic control and incidence of severe hypoglycemic events were chronologically improved, especially in female adolescents.
| INTRODUCTION
The Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) research groups recommend good glycemic control for the prevention of the onset and progression of diabetic retinopathy, nephropathy, neuropathy, and cardiovascular complications. 1, 2 Because a past of good glycemic control-known as "metabolic memory"-contributes to protect against complications, 3, 4 improvement in glycemic control for patients with childhood-onset type 1 diabetes (T1D) is particularly important.
There have been a few studies regarding the long-term efficacy of glycemic control in children with T1D, but these were only crosssectional analyses 5, 6 or included hospital-based data. 7 Further, limited cross-sectional data are available on the relation of puberty with worsened glycemic control [8] [9] [10] [11] and the risks to obese and overweight patients. [12] [13] [14] Therefore, a longitudinal study that follows pediatric patients from infancy to adolescence and focuses on the secular trend of HbA1c values is necessary. The aim of this longitudinal study was to explore chronological changes in glycemic control, clinical parameters, insulin regimens, and the incidence of severe hypoglycemic events in three cohorts of Japanese pediatric patients with T1D.
2 | METHODS
| Patients
The subjects were Japanese patients with T1D with an onset age of 16 y or younger, enrolled in three sequential cohorts in the Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes (JSGIT). 6 Table 1 re-registered from the 2000 cohort. Data on the patients whose duration of T1D was shorter than 6 mo were excluded from this study to eliminate the effect of early phase treatment. T1D was diagnosed according to the criteria of the Japan Diabetes Society (JDS) and the American Diabetes Association. Body mass index (BMI) was calculated as the weight in kilograms divided by the height in square meters. Height standard deviation score (SDS) and BMI percentile were calculated using the Japanese population data for each given age and sex, in accordance with the guidelines of the Japanese Society for Pediatric Endocrinology and the National Health and Nutrition Survey. 22, 23 Overweight and obese patients were defined as those with a BMI at the 85th percentile or greater and the 95th percentile or greater, respectively.
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Insulin regimens were classified into two groups: regimens of one to three injections per day were included in the "non-basal-bolus treatment group" and regimens including three or more administrations of bolus insulin and basal insulin per day were included in the "basal-bolus treatment group." The basal-bolus treatment group was further divided into multiple daily insulin (MDI) and continuous subcutaneous insulin infusion (CSII) groups. The type of insulins was classified as analog or non-analog. The dose of insulin was calculated as the total daily mean insulin amount in units divided by the body weight in kilograms per day (U/kg/d).
We compared longitudinal changes in HbA1c values specific sex and age in each cohort. To compare the degree of increase in the HbA1c values during puberty, pubertal increase in HbA1c was calculated in each patient using the following equation: (pubertal increase in HbA1c) = (maximum HbA1c value at the age between 11 and 15 y) − (HbA1c value at the age of 10 y). The pubertal increases in
HbA1c were compared among the three cohorts.
| Statistical analysis
We Jonckheere-Terpstra tests was used to access longitudinal trends.
Graphs of mean HbA1c values at each age were constructed to compare glycemic control in the three cohorts. All analyses were based on the assumption of missing at random. 25 Descriptive statistics are reported as the mean AE SD. Two-sided probability levels <.05 were considered statistically significant and were corrected using the Bonferroni's method for multiple comparisons. 26, 27 All statistical tests and descriptive analyses were performed using JMP software (version 11.0; SAS Institute Inc., Cary, NC, USA) or SAS statistical software (version 9.3; SAS Institute Inc.).
| Ethical approval
This observational study was approved by the review board of each participating institution in accordance with the ethical guidelines and regulations of the Declaration of Helsinki. Written consent was obtained from all patients or their parents.
3 | RESULTS
| Changes in glycemic control in the three cohorts
Glycemic control, insulin regimens and doses, height SDS, BMI, proportions of overweight and obese patients, and incidence rate of severe hypoglycemia in the 1995, 2000, and 2008 cohorts are shown in Table 2 . A trend of statistically significant improvement in HbA1c values was observed among the three cohorts (P for trend < .0001). In both sexes, a trend of decreased HbA1c values was observed (P for trend < .0001). Table 2 and Figure 1 also show the proportions of classified glycemic control (optimal, suboptimal, and high-risk groups). The proportions of optimal glycemic control had increased (P for trend < .0001). Moreover, the proportion of patients with high-risk HbA1c glycemic control tended to decrease (P for trend < .0001). Overweight patients were at the 85th BMI percentile or higher and obese patients were at the 95th BMI percentile or higher.
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin A1c; SD, standard deviation; SDS, standard deviation score. Table 2 and Figure 4 show the proportions of the patients with insulin regimens of one, two, and three times a day as well as MDI, and CSII.
| Other clinical parameters in the three cohorts
The frequencies of patients undergoing basal-bolus treatment (MDI or CSII) and the percentage of patients using insulin analogs were significantly increased (P for trend < .0001). The daily insulin dose according to weight tended to increase from the 1995 cohort to the 2008 cohort (P for trend = .0009) ( Table 2) 
| DISCUSSION
In this study, glycemic control of pediatric patients with T1D tended to improve among the 1995 to 2008 cohorts. Notably, the pubertal increase in HbA1c values in female patients tended to decrease among the sequential cohorts. The findings of this study also indicated that the improvement in glycemic control and decreased incidence rate of severe hypoglycemic events can be attributed to the increased use of basal-bolus insulin regimens using insulin analogs with sufficient dosages. FIGURE 1 Proportions of glycemic control for glycated hemoglobin A1c (HbA1c) values according to International Society for Pediatric and Adolescent Diabetes (ISPAD) criteria. Glycemic control was categorized into three ranges: an optimal group, with HbA1c values <58 mmol/mol (<7.5%); a suboptimal group with HbA1c values of 58-75 mmol/mol (7.5-9.0 mmol/mol); and a high-risk group, with HbA1c values >75 mmol/mol (>9.0%). P for trend <.0001. 
| Strengths and limitations
To the best of our knowledge, this is the first multicenter survey of glycemic control and treatments of Japanese childhood-onset T1D. This study is strengthened by several aspects. First, this study from a number of institutions followed up more than 500 patients; thus, it is the largest cohort to date in Japan, where T1D is a regarded as a relatively rare disease compared with that in western countries. 28 Second, the measured HbA1c values at each institution were standardized by careful calibrations, which enhanced the accuracy of the present results. Third, it was found that the pubertal increase in HbA1c had improved from 1995 to 2008 in Japan.
Several limitations should be considered when interpreting the results of this study. First, the institutions participating in the present study may not represent the majority of Japanese hospitals. However, because Japanese patients with T1D are usually followed up in specialized institutions, we believe that the three cohorts have registered most T1D patients. As a second limitation, uncontrolled T1D cases may have dropped out. However, we consider that the comparability of the three cohorts would be preserved when the data were missing at random. Third, the measured insulin doses may not be accurate because the information on total daily insulin dose were not from CSII devices but rather self-reports by the patients. Because the variation of day-to-day dose could be large among individual patients, the individual dose were not easily determined. Fourth, this analyses of the three cohorts did not assess ultra-long-acting insulin analogs (eg, degludec), which have been reported as safe and effective for children, 29 and have been covered by the Japanese National Health Insurance Program since 2013. Nonetheless, we consider that we sufficiently evaluated the effects of long-acting insulin analogs.
| Possible mechanism underlying the improvement in glycemic control
The observed improvement in glycemic control may be because of the increased frequency of the basal-bolus insulin regimens using insulin analogs, which mimic the physiological insulin response to glycemic changes in non-diabetic patients. The pediatricians of the JSGIT have been intensively introducing MDI to their patients since 1993. 6 In Japan, rapid-acting insulin analog was introduced in 2001 and the use of a long-acting insulin analog was started in 2003. Blood concentration of rapid-acting insulin analogs (eg, lispro) rises sharply and drops precipitously 30 without increasing the risk of severe hypoglycemic events. 31 On the other hand, the use of long-acting insulin analog (eg, glargine and detemir) enables diabetic patients to maintain peak-less basal insulin levels with fewer hypoglycemic events. 32, 33 The combination of the two above-mentioned insulin analogs also enables patients to receive insulin while eating snacks. According to this data, the proportion of basal insulin in the total daily insulin dose among the patients who received basal-bolus treatment was 35% in 2000 and 38% in 2008 (data not shown), and the proportions were similar to that for 27.7% of Japanese adult patients with T1D patients who treated with CSII. 34 In contrast, the proportion of basal insulin is reported
to be approximately 50% in western countries. 35 In Japan, such a low proportion of basal insulin requirement may have exerted a favorable effect on glycemic control among Japanese children with T1D. To assess the efficacy of treatment, the Hvidøre Study Group proposed a new classification for insulin regimens and emphasized the importance of patient education and skill training. 36 In addition, Keller et al. concluded that general health perception was more strongly associated with improvement in glycemic control than insulin regimens and diabetes knowledge. In contrast to these reports, our data suggest that improved glycemic control was associated with progress and development of treatment, especially basal-bolus treatment with insulin analogs. 37 We consider that the observed improvement in glycemic control in this study was also associated with general health perception resulting from safety treatment with rapid-and long-acting insulin analogs without hypoglycemia, particularly in adolescents.
Particularly in Japanese adolescents with T1D, the following factors were considered to contribute to the chronological improvement in glycemic control. First, because most diabetic patients visit a hospital or clinic monthly, they could easily manage their insulin regimens and receive face-to-face medical advice throughout puberty when 
| Improvement of clinical parameters
Although the height SDS of the patients in the 1995 cohort was below the average of the Japanese children, the height SDS was sig- This increase in BMI was thought to be partly because of sufficient insulin dosages. Although the levels of BMI in Japanese obese children with T1D is relatively moderate in comparison with that in western countries, 12 it is important to continuously monitor patients to prevent obesity when they approach adulthood.
| Consistency with previous studies
A cross-sectional report on long-term glycemic control in adult Japa- ( Figures 2 and 3) . Although the latest report of American children with T1D showed that the pubertal increase of HbA1c had decreased from 1995 to 2004, 42 the pubertal increase in HbA1c among Japanese children is less than that in western patients. 42, 43 Further, the control of plasma glucose in female adolescents is considered more difficult than that in male adolescents because insulin resistance is greater. 44 The marked improvement in HbA1c values among the female adolescents included in the 2008 cohort was probably because of basal-bolus regimens with insulin analogs, which provided easier glycemic control with less frequent hypoglycemic events.
| CONCLUSIONS
This study revealed an improvement in glycemic control and a decreased incidence rate of severe hypoglycemic events among Japanese pediatric patients with T1D. This improved glycemic control was probably because of the developed basal-bolus treatment regimens with insulin analogs. The improvement was more pronounced in Japanese pubescent female patients.
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